本文選題：吲達(dá)帕胺 + 貝那普利�。� 參考：《中國(guó)藥房》2017年21期

【摘要】：目的:比較吲達(dá)帕胺分別聯(lián)合貝那普利、厄貝沙坦、氨氯地平治療2級(jí)原發(fā)性高血壓(EH)的療效和安全性。方法:150例2級(jí)EH患者隨機(jī)分為貝那普利組(50例)、厄貝沙坦組(50例)和氨氯地平組(50例)。3組患者均給予吲達(dá)帕胺片2.5 mg,口服,每日1次。在此基礎(chǔ)上,貝那普利組患者口服鹽酸貝那普利片10 mg,每日1次;厄貝沙坦組患者口服厄貝沙坦片150 mg,每日1次;氨氯地平組患者口服氨氯地平片5 mg,每日1次。3組療程均為12周。觀察3組患者治療前后收縮壓、舒張壓、心率、總膽固醇(TC)、三酰甘油(TG)、血鉀水平及不良反應(yīng)發(fā)生情況。結(jié)果:貝那普利組、厄貝沙坦組和氨氯地平組患者總有效率比較,差異無統(tǒng)計(jì)學(xué)意義(90.0%vs.88.0%vs.92.0%,P0.05)。治療前,3組患者收縮壓、舒張壓、心率、TC、TG、血鉀水平比較,差異均無統(tǒng)計(jì)學(xué)意義(P0.05)。治療后,3組患者收縮壓、舒張壓均顯著低于同組治療前,差異均有統(tǒng)計(jì)學(xué)意義(P0.05);但3組間比較差異均無統(tǒng)計(jì)學(xué)意義(P0.05)。3組患者治療前后心率、TC、TG及貝那普利組、厄貝沙坦組治療前后血鉀比較,差異均無統(tǒng)計(jì)學(xué)意義(P0.05)。氨氯地平組患者血鉀水平顯著低于同組治療前,差異有統(tǒng)計(jì)學(xué)意義(P0.05)。厄貝沙坦組患者不良反應(yīng)發(fā)生率顯著低于貝那普利組和氨氯地平組,差異有統(tǒng)計(jì)學(xué)意義(P0.05),但貝那普利組與氨氯地平組間比較,差異無統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論:吲達(dá)帕胺分別聯(lián)合貝那普利、厄貝沙坦、氨氯地平治療2級(jí)EH的療效相當(dāng),但厄貝沙坦組的安全性優(yōu)于貝那普利組和氨氯地平組。
[Abstract]:Aim: to compare the efficacy and safety of indapamide combined with benazepril irbesartan and amlodipine in the treatment of grade 2 essential hypertension. Methods one hundred and fifty patients with grade 2 EH were randomly divided into benazepril group (n = 50) and irbesartan group (n = 50) and amlodipine group (n = 50) were treated with indapamide 2.5 mg orally once a day. On this basis, benazepril group took 10 mg benazepril hydrochloride once a day, irbesartan group 150 mg of irbesartan tablets once a day. Amlodipine group was treated with amlodipine tablets (5 mg) once a day for 12 weeks. Systolic blood pressure, diastolic blood pressure, heart rate, total cholesterol TCU, triglyceride TGN, serum potassium level and adverse reactions were observed before and after treatment. Results: the total effective rate of benazepril group, irbesartan group and amlodipine group was not significantly different from that of benazepril group, irbesartan group and amlodipine group. There was no significant difference in the total effective rate of benazepril group, irbesartan group and amlodipine group. There was no significant difference in systolic blood pressure, diastolic blood pressure, heart rate, TCU TGand serum potassium levels between the three groups before treatment (P 0.05). After treatment, systolic blood pressure and diastolic blood pressure in the three groups were significantly lower than those in the same group before and after treatment, and the differences were statistically significant (P 0.05), but there was no significant difference between the three groups in heart rate TCTG and benazepril before and after treatment. In irbesartan group, there was no significant difference in serum potassium before and after treatment (P 0.05). The serum potassium level in amlodipine group was significantly lower than that in the same group before treatment (P 0.05). The incidence of adverse reactions in irbesartan group was significantly lower than that in benazepril group and amlodipine group (P 0.05), but there was no significant difference between benazepril group and amlodipine group. Conclusion: the efficacy of indapamide combined with benazepril irbesartan and amlodipine in the treatment of grade 2 EH is similar but the safety of irbesartan group is better than that of benazepril group and amlodipine group.
【作者單位】： 廣西壯族自治區(qū)桂東人民醫(yī)院內(nèi)科;
【分類號(hào)】：R544.11

【參考文獻(xiàn)】

相關(guān)期刊論文 前9條

1 劉俊燕;栗娜;;苯磺酸氨氯地平聯(lián)合賴諾普利氫氯噻嗪與阿托伐他汀治療重度原發(fā)性高血壓合并頸動(dòng)脈粥樣硬化的臨床觀察[J];中國(guó)藥房;2017年09期

2 徐丹;黃龍賢;周大燕;屈宗杰;;瑞格列奈分別聯(lián)合氨氯地平、氯沙坦鉀治療T2DM合并原發(fā)性高血壓的療效和安全性比較[J];中國(guó)藥房;2017年03期

3 彭夫松;楊磊磊;孫劍笠;張利利;魏霄瑾;;纈沙坦與氨氯地平治療原發(fā)性高血壓的比較研究[J];現(xiàn)代藥物與臨床;2016年08期

4 趙連友;王文;孫寧玲;李玉明;謝良地;馮穎青;蘇海;李悅;盧新政;;鈣拮抗劑/血管緊張素轉(zhuǎn)換酶抑制劑單片復(fù)方制劑在高血壓治療中的應(yīng)用中國(guó)專家建議[J];中華高血壓雜志;2016年01期

5 蘇津自;;血管緊張素轉(zhuǎn)換酶抑制劑+利尿劑好,還是血管緊張素受體拮抗劑+利尿劑好?[J];中華高血壓雜志;2016年01期

6 趙蘇;楊婉花;陳冰;;貝那普利對(duì)比卡托普利治療原發(fā)性高血壓療效與安全性的Meta分析[J];中國(guó)藥房;2015年18期

7 牟建軍;;降壓達(dá)標(biāo)治療路徑:是增加一種降壓藥至最大劑量還是盡早聯(lián)合應(yīng)用[J];中華高血壓雜志;2014年11期

8 黃建波;;吲達(dá)帕胺聯(lián)合氨氯地平片治療高血壓合并冠心病的臨床療效[J];中國(guó)現(xiàn)代藥物應(yīng)用;2013年17期

9 劉力生;;中國(guó)高血壓防治指南2010[J];中華高血壓雜志;2011年08期

【共引文獻(xiàn)】

相關(guān)期刊論文 前10條

1 蘇偉;;β受體阻滯劑聯(lián)合ACEI治療高血壓的研究進(jìn)展[J];中國(guó)城鄉(xiāng)企業(yè)衛(wèi)生;2017年08期

2 李U，

本文編號(hào)：1948446